Look for Drugs and Conditions

Lenvatinib

Lenvatinib

Lenvatinib is anticancer drug which is multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.

Indications

locally recurrent or metastatic, progressive, radioactive iodine-refractory Differentiated Thyroid Carcinoma, in combination with everolimus for the treatment of patients with advanced Renal cell carcinoma following one prior anti-angiogenic therapy.


Dosage

Oral; 14-28 mg daily dose modification to be done according to grade of carcinoma.


Contra-Indications

Data not sufficient.


Special Precautions

Paediatric: safety and effectiveness in pediatric patients have not been established. Pregnancy: No human data available. It has teratogenic effect in animal studies. Lactation: advise women to discontinue breastfeeding during treatment. Elderly: No difference in safety and efficacy was found in young and elderly people.


Side Effects

Hypertension, Cardiac Dysfunction, Arterial Thromboembolic Events, Hepatotoxicity , Proteinuria , Diarrhea, Renal Failure and Impairment, diarrhea, fatigue, Gastrointestinal Perforation and Fistula Formation, QT Interval Prolongation, Hypocalcemia, Reversible Posterior Leukoencephalopathy Syndrome, Hemorrhagic Events, Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction, Wound Healing Complications.


Drug Interactions

Data not sufficient.


Other Brands With Same Generic
Brand Name Manufactured by
LENVENIB Sun Pharmaceutical Industries Ltd.
Ad 5